Physician profile
Adil Abdalla
NPI 1245215292
$8,570.39
in general payments reported to CMS, 2019-2025
35 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $420 · 2021: $1,307 · 2022: $1,909 · 2023: $1,485 · 2024: $1,697 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,417 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,417.03 |
| Education | $126.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,356.26 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $711.75 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $709.48 | 2019-2025 | |
| Janssen Biotech, INC. | $394.81 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $371.98 | 2019-2025 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $324.47 | 2020-2023 | Givlaari |
| Regeneron Healthcare Solutions, INC. | $290.68 | 2022-2024 | Dupixent |
| Genzyme Corporation | $245.51 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $239.11 | 2020-2025 | Ocaliva |
| Mallinckrodt Hospital Products INC. | $233.08 | 2023-2025 | Terlivaz |
| Nestle Healthcare Nutrition INC. | $229.46 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $147.09 | 2023-2025 | Iqirvo, Bylvay |
| Medtronic, INC. | $139.98 | 2024-2025 | Interstim |
| Boston Scientific Corporation | $133.41 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $109.13 | 2022-2024 | Sutab, Suflave |
| Celgene Corporation | $98.17 | 2022-2023 | Zeposia |
| Qol Medical, LLC | $86.80 | 2022-2024 | Sucraid, Sucraid |
| Lilly USA, LLC | $74.05 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $71.57 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $63.17 | 2021-2024 | Dificid |
| Aimmune Therapeutics, INC. | $57.70 | 2024-2025 | Vowst |
| Madrigal Pharmaceuticals | $57.68 | 2025 | Rezdiffra |
| Ardelyx, INC. | $51.34 | 2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $37.83 | 2019-2023 | Rebyota |
| Novo Nordisk INC | $32.27 | 2025 | Wegovy |
| Redhill Biopharma INC. | $26.53 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Echosens North America, INC. | $24.83 | 2024 | Fibroscan |
| Organon LLC | $23.72 | 2023 | Hadlima |
| Phathom Pharmaceuticals, INC. | $21.43 | 2024 | Voquezna |
| Fresenius Kabi USA, LLC | $19.93 | 2023 | |
| Welch Allyn | $16.90 | 2021 | |
| Pfizer INC. | $16.23 | 2024 | |
| Ucb, INC. | $15.71 | 2019 | |
| Evoke Pharma, INC. | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adil Abdalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.